After some very public cajoling, executives from some of the world’s largest drug makers have now agreed to testify about drug pricing at a Senate hearing later this month.

Of course, they would be foolish not to do so. The Senate Finance Committee leadership is not especially friendly to the pharmaceutical industry, which is already under siege. Showing up is simply smart politics in the face of proposals and legislation that could change the way they do business.